Despite widespread dissemination in the environment, Acanthamoeba are a rare cause of human diseases. Amebic keratitis (AK), granulomatous amebic encephalitis (GAE) with or without dissemination, and skin lesions are the most commonly reported clinical patterns (1, 2) . W|th the exception of AK, infection with Acanthamoeba has been reported primarily in immunosuppressed patients. Most reports have been in patients with acquired immunode¢-ciency syndrome (AIDS), and only 4 patients, all post mortem, with GAE with or without disseminated disease after bone marrow or hematopoietic stem cell transplant (HSCT) have been described (2^9).
While no standard treatment for infection with Acanthamoeba has been described, a variety of agents have activity in vitro, in animal models, or have shown success in case reports (10^16). Recently, a case report suggested clinical response to voriconazole and amphotericin B in a lung transplant patient with skin lesions, and in vitro activity of voriconazole against some species of Acanthamoeba has been described (13, 15) . We report the ¢rst case of Acanthamoeba infection in a peripheral blood stem cell transplant (PBSCT) recipient diagnosed ante-mortem. In this patient, probable GAE with con¢rmed skin and pulmonary lesions developed despite the long-term prophylactic use of voriconazole to prevent invasive fungal infection in the setting of chronic graft-versus-host disease (GVHD).
Case report
The patient was a 53 -year-old man with a history of acute lymphocytic leukemia who received a matched unrelated donor for PBSCT 930 days before presentation. The patient's post-transplant course was complicated by extensive chronic GVHD of the skin, eyes, mouth, and liver. The patient's home regimen of immunosuppression included tacrolimus 0.5 mg twice daily, mycophenolate mofetil 1 g twice daily, and methylprednisolone 20 mg daily. As antimicrobial prophylaxis, the patient was taking voriconazole 200 mg twice daily, acyclovir 400 mg twice daily, penicillin V 500 mg twice daily, and trimethoprim/ sulfamethoxazole (TMP/SMX) 1 double-strength tablet twice a day on 2 days a week.
The patient was admitted to the hospital with sepsis and had bacteremic Pseudomonas aeruginosa pneumonia requiring mechanical ventilation. Because the patient remained poorly responsive, computed tomography (CT) of the head was performed and revealed an area of hyperdensity in the left periventricular area suggestive of subacute hemorrhage. Magnetic resonance imaging con¢rmed this impression, and because of hemorrhage, no comment on enhancement could be made (F|g. 1).
The patient's mental status improved and 3 days later he was transferred out of the intensive care unit. He developed fewer than 10 papular and ulcerated skin lesions on his face, leg, and arms (F|g. 2); biopsy was performed. Hematoxylin and eosin staining revealed amebic trophozoites and cyst forms (F|g. 3). Immunohistochemistry staining con¢rmed infection with Acanthamoeba (not shown).
The patient was started on treatment with liposomal amphotericin B (Ambisome) 5 mg/kg daily in combination with TMP/SMX (5 mg/kg of the trimethoprim component) every 8 h. The patient received 3 weeks of treatment without signi¢cant change in the skin or central nervous system (CNS) lesions, although no new skin lesions were observed. Miltefosine 100 mg daily was obtained with US Food and Drug Administration (FDA) approval for emergency use, and TMP/SMX and liposomal amphotericin were discontinued and voriconazole 300 mg twice daily was restarted.
The patient developed worsening pulmonary status and patchy in¢ltrates on CT of the chest and was treated with ceftazadime 2 g every 8 h, and amikacin 500 mg inhaled twice a day. Over the next 2 weeks, the patient's condition deteriorated, and he developed mental status changes and increasing oxygen requirements. The patient died 5 weeks after the diagnosis of Acanthamoeba was originally made.
Autopsy was performed, and examination of the brain revealed hemorrhagic necrosis; the histology was consistent with GAE, but no organisms were identi¢ed in or near the hemorrhage (F|g. 4). In the lungs, areas of necrosis and consolidation were not visible grossly, but all random lung sections from both lungs contained Acanthamoeba cysts and trophozoites (F|g. 5).
Discussion
Infection secondary to Acanthamoeba is rare and very di⁄cult to diagnose, and we present to our knowledge the ¢rst case diagnosed ante-mortem in a PBSCT or bone marrow transplant recipient. Diagnosis is generally made by observing trophozoites or cysts on tissue specimens. Particularly in patients with hematological malignancies, thrombocytopenia or poor overall condition, the opportunity to obtain a brain biopsy may be limited. Moreover, even if a biopsy is obtained, sampling area or failure to recognize the pathogen may limit diagnostic yield (17 ) . In our case, diagnosis was only made possible by the presence of skin lesions that could be easily biopsied with little risk to the patient.
Acanthamoeba are free-living ameba widely distributed in the environment. They have been isolated in soil and virtually any water source (e.g., tap or bottled water, contact lens solutions) (2).Thus, in most cases not involving contact lens solution, no speci¢c exposure is identi¢ed. The most common clinical disease caused by Acanthamoeba is AK, which is related to contact lens use and generally occurs in immunocompetent individuals (2) . CNS involvement, in contrast, usually occurs in immunosuppressed individuals, and typically presents as a subacute meningoencephalitis with ring enhancing or hemorrhagic lesions. Skin lesions with or without CNS lesions have also been described (2, 15) . Lung involvement, as occurred in our patient, has been described in patients with GAE (2, 3). While GAE was not proven by biopsy or autopsy in our case, a subacute CNS hemorrhage in an unusual location in the context of heavy immunosuppression, and cutaneously disseminated Acanthamoeba is suggestive of GAE.
Although AIDS is the most commonly reported risk factor for non-ocularAcanthamoeba, other risk factors include solid organ transplantation, connective tissue disease, diabetes, cirrhosis, renal failure, malignancies, and tuberculosis (1, 2, 18^21) . CNS or disseminated disease may occur in immunocompetent patients, but is rare.Three other reports describe 4 patients with disease caused by Acanthamoeba after HSCT or bone marrow transplant (Table 1) (3, 4, 9) . Interestingly, 3 of the 5 patients (including this report) had proven Acanthamoeba pneumonia at autopsy, and nodular in¢ltrates were noted weeks before the development of mental status changes. The range of time from ¢rst likely clinical manifestation to death was 11^82 days. In all cases except ours, diagnosis was made on post-mortem examination, so no comments regarding the e⁄cacy of treatment can be made.
An instructive aspect of our case is the occurrence of Acanthamoeba infection in a patient with GVHD treated with long-term voriconazole as prophylaxis (200 mg twice a day) against invasive fungal infection. The antifungal activity of voriconazole is based on inhibition of synthesis of ergosterol, which is also present in the plasma membrane of Acanthamoeba, providing a theoretical rationale for the anti-amebic activity of voriconazole observed in vitro (13) . In one study, the in vitro activity of voriconazole was observed in 3 species of Acanthamoeba representative of the species most commonly found in clinical isolates (13) . A case report demonstrated obvious improvement in cutaneous lesions in a lung transplant patient with skin disease treated with the combination of lipid amphotericin B and voriconazole (15) . Our case, however, suggests that voriconazole may not always be e¡ective. This may be sec- ondary to poor absorption of the drug, inadequate dose, the overall state of immunosuppression of the patient, or poor activity against the particular species of Acanthamoeba infecting our patient. Miltefosine (hexadecylphosphocholine) is an anti-neoplastic agent that has been used to treat visceral leishmaniasis, and has in vitro activity against Acanthamoeba species, and clinical success has been described in a single case report (13, 16) . The drug is not FDA-approved for use for any indication in the United States, but may be obtained for emergency use through the FDA. As Acanthamoeba cannot be grown in culture in clinical microbiology labs, susceptibility testing is generally not available.
Conclusion
We describe the ¢rst case, to our knowledge, of infection with Acanthamoeba diagnosed ante-mortem in an HSCT recipient. A high index of suspicion is necessary to make this diagnosis. Disease developed despite long-term prophylactic administration of voriconazole, and the patient did not respond to combination therapy with multiple agents reported to have activity against Acanthamoeba in vitro, in animal models, or in clinical case reports. 
